These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23985909)

  • 1. Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay.
    Zhang G; Cai F; Zhou Z; DeVos J; Wagar N; Diallo K; Zulu I; Wadonda-Kabondo N; Stringer JS; Weidle PJ; Ndongmo CB; Sikazwe I; Sarr A; Kagoli M; Nkengasong J; Gao F; Yang C
    J Clin Microbiol; 2013 Nov; 51(11):3666-74. PubMed ID: 23985909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY® System.
    Cheung KW; Peng Q; He L; Cai K; Jiang Q; Zhou B; To SW; Yam WC; Liu L; Chen Z; Wang H
    PLoS One; 2016; 11(4):e0153641. PubMed ID: 27092551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey.
    Sayan M; Sargin F; Inan D; Sevgi DY; Celikbas AK; Yasar K; Kaptan F; Kutlu S; Fisgin NT; Inci A; Ceran N; Karaoglan I; Cagatay A; Celen MK; Koruk ST; Ceylan B; Yildirmak T; Akalın H; Korten V; Willke A
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):26-31. PubMed ID: 26414663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
    Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
    Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
    Hunt GM; Morris L; Moorthy A; Coovadia A; Abrams EJ; Strehlau R; Kuhn L; Persaud D
    J Virol Methods; 2014 Oct; 207():182-7. PubMed ID: 25034127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.
    Lee JH; Hachiya A; Shin SK; Lee J; Gatanaga H; Oka S; Kirby KA; Ong YT; Sarafianos SG; Folk WR; Yoo W; Hong SP; Kim SO
    Clin Microbiol Infect; 2013 Jun; 19(6):E263-70. PubMed ID: 23480551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of the oligonucleotide ligation assay for detection of the M184V drug-resistant mutation in patients infected with human immunodeficiency virus type 1 subtype CRF01_AE.
    Dokuta S; Utaipat U; Praparattanapan J; Keitkarn J; Maneekarn N; Sirisanthana T; Supparatpinyo K
    J Virol Methods; 2013 Jun; 190(1-2):20-8. PubMed ID: 23562659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous and sensitive detection of human immunodeficiency virus type 1 (HIV) drug resistant genotypes by multiplex oligonucleotide ligation assay.
    Ellis GM; Vlaskin TA; Koth A; Vaz LE; Dross SE; Beck IA; Frenkel LM
    J Virol Methods; 2013 Sep; 192(1-2):39-43. PubMed ID: 23660583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay.
    Kiertiburanakul S; Pinsai S; Chantratita W; Pasomsub E; Leechawengwongs M; Thipmontree W; Siriyakorn N; Sungkanuparph S
    PLoS One; 2016; 11(2):e0147945. PubMed ID: 26828876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.
    Santoro MM; Alteri C; Ronga L; Flandre P; Fabeni L; Mercurio F; D'Arrigo R; Gori C; Palamara G; Bertoli A; Forbici F; Salpini R; Boumis E; Tozzi V; Visco-Comandini U; Zaccarelli M; Van Houtte M; Pattery T; Narciso P; Antinori A; Ceccherini-Silberstein F; Perno CF
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1285-93. PubMed ID: 22417570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.
    Ibe S; Sugiura W
    Future Microbiol; 2011 Mar; 6(3):295-315. PubMed ID: 21449841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of amplification refractory mutation system PCR assay as a simple and effective tool to detect HIV-1 drug resistance mutations.
    Nanfack AJ; Agyingi L; Noubiap JJ; Ngai JN; Colizzi V; Nyambi PN
    J Clin Microbiol; 2015 May; 53(5):1662-71. PubMed ID: 25788547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia.
    Mohamad S; Deris ZZ; Yusoff NK; Ariffin TA; Shueb RH
    Braz J Infect Dis; 2012; 16(3):284-8. PubMed ID: 22729198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes.
    Aitken SC; Kliphuis A; Wallis CL; Chu ML; Fillekes Q; Barth R; Stevens W; Rinke de Wit TF; Schuurman R
    J Clin Virol; 2012 May; 54(1):21-5. PubMed ID: 22306272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation patterns of the reverse transcriptase genes in HIV-1 infected patients receiving combinations of nucleoside and non nucleoside inhibitors.
    Re MC; Bon I; Monari P; Borderi M; Gibellini D; Schiavone P; Vitone F; Chiodo F; La Placa M
    Int J Antimicrob Agents; 2003 Oct; 22(4):388-94. PubMed ID: 14522102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan.
    Nishizawa M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
    PLoS One; 2013; 8(12):e83150. PubMed ID: 24358257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.
    Chaplin B; Eisen G; Idoko J; Onwujekwe D; Idigbe E; Adewole I; Gashau W; Meloni S; Sarr AD; Sankalé JL; Ekong E; Murphy RL; Kanki P
    AIDS Res Hum Retroviruses; 2011 Jan; 27(1):71-80. PubMed ID: 20964479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
    Deletsu SD; Maina EK; Quaye O; Ampofo WK; Awandare GA; Bonney EY
    Medicine (Baltimore); 2020 Feb; 99(7):e18777. PubMed ID: 32049783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.